Arcadia Biosciences (RKDA) Collaborates with GoodMills Innovation to Sell GoodWheat™ in Europe
Arcadia Biosciences (Nasdaq: RKDA) has announced a partnership with GoodMills Innovation to commercialize their nutritional wheat products in Europe. This collaboration aims to introduce the GoodWheat™ portfolio, which features healthier wheat options with enhanced fiber content, lower calories, and reduced allergenicity. The European milling industry, producing 35 million tons of flour annually, presents a significant opportunity for growth. CEO Matthew Plavan emphasized the innovative potential of this partnership to meet rising consumer demand for healthier food options.
- Collaboration with GoodMills Innovation to commercialize GoodWheat™ in Europe.
- GoodWheat™ includes health benefits like higher fiber and fewer calories.
- GoodMills is Europe’s largest milling company, providing a robust market opportunity.
- Dependence on successful regulatory approval for GoodWheat™ products.
- Market demand and competition may impact sales of GoodWheat™.
- COVID-19's potential impact on business operations.
DAVIS, Calif., Aug. 12, 2020 /PRNewswire/ -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today announced a collaboration with GoodMills Innovation, an affiliate of GoodMills Group, Europe's largest milling company, for commercialization of wheat with improved nutritional value across Europe.
"We are pleased to be working with GoodMills to introduce valued nutritional benefits to wheat-based products across Europe," said Matthew Plavan, president and CEO of Arcadia Biosciences. "GoodMills is an excellent partner with a strong focus on innovation. Together we aim to introduce uniquely healthy products for the retail, consumer and food service sectors in Europe, beginning in 2020."
The GoodWheat™ portfolio of good-for-you wheats includes attributes such as higher fiber, fewer calories and reduced allergenicity, as well as extended shelf life. The ingredients are the output of Arcadia's proprietary ArcaTech™ platform, which accelerates discovery, development and breeding of new wheat varieties using advanced non-GM techniques.
"GoodMills Innovation is recognized as one of the world's leading innovators in the area of grain-based ingredients that are both highly functional and nutritional," said Michael Gusko, head of innovation at GoodMills. "Recent market research highlights accelerated key consumer trends in 2020, including health and immunity enhancement, natural authentic cooking and sustainable plant protein. We see tremendous potential in Arcadia's portfolio of specialty wheats to help us meet these trends."
The European milling industry produces 35 million tons of flour on an annual basis with a turnover of
About Arcadia Biosciences, Inc.
Arcadia Biosciences (Nasdaq: RKDA) is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company's GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. Arcadia's agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. The company's GoodHemp™ seed catalog delivers genetically superior hemp seeds, clones, transplants, flower and extracts, applying the company's proprietary crop innovation technology, ArcaTech™, to an emerging crop. For more information, visit www.arcadiabio.com.
About The GoodMills Group
The GoodMills Group GmbH is a holding company, managing seven country organizations with, in total, twenty-five flour mills. It is the leading milling company in Europe, processing 2.9 million tons of grain and generating
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the commercial success of the intended collaboration between GoodMills and Arcadia. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia's and its partners' and affiliates' ability to develop and sell commercial products incorporating their traits, and complete the regulatory review process for such products; the successful negotiation and completion of definitive agreements with respect to the collaboration with GoodMills; the demand for our GoodWheat products in Europe; Arcadia's compliance with laws and regulations that impact Arcadia's business, and changes to such laws and regulations; the potential impact of COVID-19 on our business; and the company's future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company's financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled "Risk Factors" and additional information set forth in its Form 10-K for the year ended December 31, 2019 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.
LinkedIn: Arcadia Biosciences
Twitter: @ArcadiaAg
View original content to download multimedia:http://www.prnewswire.com/news-releases/arcadia-biosciences-rkda-collaborates-with-goodmills-innovation-to-sell-goodwheat-in-europe-301110667.html
SOURCE Arcadia Biosciences, Inc.
FAQ
What is the collaboration between Arcadia Biosciences and GoodMills about?
What are the benefits of GoodWheat™ from Arcadia Biosciences?
When was the partnership between Arcadia Biosciences and GoodMills announced?
What market opportunity does this collaboration target?
What are the risks associated with the Arcadia Biosciences and GoodMills collaboration?
